This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers rides growth brands like Opdivo and Reblozyl to offset generics, with pipeline catalysts and cost cuts shaping its next phase.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Kimco Realty (KIM) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KIMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
LMATNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is Novo Nordisk's GLP-1 Dominance Fading After Lilly's Clinical Wins?
by Ahan Chakraborty
NVO shares plunge 21% after Lilly's Zepbound and oral orforglipron beat its key GLP-1 drugs in head-to-head obesity and diabetes studies, respectively.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
by Santanu Roy
Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.
CVXPositive Net Change ANGONegative Net Change PGNegative Net Change AMGNNegative Net Change DEPositive Net Change PEPNegative Net Change CHDNegative Net Change FCFSPositive Net Change NOBLNegative Net Change SUZNegative Net Change NTSTPositive Net Change CTNMNo Net Change
biotechnology business-services consumer-staples industrial-products medical medical-devices oil-energy reit
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
PCRXNegative Net Change USNANegative Net Change CSTLNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
NBIXPositive Net Change USNANegative Net Change XENENegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway
by Zacks Equity Research
KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.
SNYNegative Net Change GILDPositive Net Change CSTLNegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
Denali posts narrower-than-expected Q4 loss as FDA extends review of tividenofusp alfa, with $966M cash backing pipeline advances and no Q4 revenues.
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
by Zacks Equity Research
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
ANIPPositive Net Change ALLONegative Net Change CSTLNegative Net Change VTRSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals